



POLIO GLOBAL
ERADICATION
INITIATIVE

Polio Eradication Strategy 2022–2026

**Delivering on
a promise**





POLIO GLOBAL
ERADICATION
INITIATIVE

Polio Eradication Strategy 2022–2026

**Delivering on
a promise**



Polio Eradication Strategy 2022–2026: Delivering on a promise

ISBN 978-92-4-003193-7 (electronic version)

ISBN 978-92-4-003194-4 (print version)

Published by the World Health Organization (WHO) on behalf of the Global Polio Eradication Initiative (GPEI).

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Polio Eradication Strategy 2022–2026: Delivering on a promise. Geneva: World Health Organization; 2021. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This report reflects contributions from a process led by the GPEI agency partners: Rotary International, WHO, the US Centers for Disease Control and Prevention (CDC), the United Nations Children's Fund (UNICEF), the Bill & Melinda Gates Foundation, and Gavi, the Vaccine Alliance.

Design and layout by Evalueserve.

Cover photo credits: UNICEF Pakistan / Syed Mehdi Bukhari

CONTENTS

Foreword.....	v
Acknowledgements.....	vi
Acronyms and abbreviations.....	vii
Executive summary.....	ix
Overview.....	1
Goal One: Permanently interrupt all poliovirus transmission in endemic countries	7
Epidemiological context	7
Current challenges	7
Path to permanently interrupt all poliovirus transmission in endemic countries.....	8
1. Create urgency and accountability through advocacy to generate greater political will	10
2. Generate vaccine acceptance through context-adapted community engagement	12
3. Improve frontline success through changes to campaign operations.....	14
4. Expedite progress through expanded integration efforts and unified partnerships	15
5. Improve detection and response through sensitive surveillance.....	17
Goal Two: Stop cVDPV transmission and prevent outbreaks in non-endemic countries.....	19
Epidemiological context	19
Current challenges	19
Path to stop cVDPV2 transmission and prevent outbreaks in non-endemic countries	20
1. Create urgency and accountability through advocacy to generate greater political will	21
2. Improve detection and response through sensitive surveillance	22
3. Improve frontline success through changes to outbreak response operations.....	24
4. Generate vaccine acceptance through context-adapted community engagement	27
5. Expedite progress through expanded integration efforts and unified partnerships.....	29
Enabling environment	31
1. GPEI structure.....	31
2. Gender equality	32
3. Communications	33
4. Vaccine supply	34
5. Research.....	36
6. Monitoring and evaluation framework.....	36
7. Finance and costing	38
Preparing for the post-certification world	40
Containing poliovirus	41
OPV cessation	42
Annex A. Stakeholder consultation list.....	43
Annex B. Current epidemiological state.....	44
Annex C. Immunization Agenda 2030.....	46
Annex D. Integration.....	47
Annex E. Risks.....	50
Annex F. Strategy objectives and key performance indicators	54
Annex G. nOPV2 contingency planning.....	58
Annex H. Management review	60
Annex I. Gender mainstreaming	62
Annex J. Research and development	63
Annex K. Polio containment update	66



© UNICEF Pakistan / Syed Mehdi Bokhari

FOREWORD

The promise of a polio-free world has been a driving force behind the Global Polio Eradication Initiative (GPEI), contributing to critical health gains over the past three decades. Indeed, before the coronavirus disease (COVID-19), polio eradication signified to many what the world could achieve by joining together to protect and promote the health of all children.

As the world – and especially country health systems – adjusted to a new global health threat in COVID-19, the GPEI launched an intensive review to identify barriers to eradication and develop a new strategy to deliver on the promise of a polio-free world. The complexity of the task grew as the programme had to take inventory of challenges faced in the years before COVID-19 and define solutions that will work in a world perhaps forever altered in the wake of COVID-19. Without a doubt, the single greatest asset for this exercise has been more than 300 stakeholders who, through interviews, workshops and reviews, lent knowledge and insight into the new and unfamiliar terrain of eradicating polio while mitigating the risks and responding to the needs of a global pandemic.

Over the past few months, it has become clear that to place the GPEI back on the path to eradication, we must operate with an emergency tempo while also becoming more accountable to the collective partnership, more responsive to the intersecting needs of impacted communities, more welcoming of intersecting fields of expertise, and more integrated with social and health programmes that deliver critical interventions to vulnerable populations.

The **Polio Eradication Strategy 2022–2026** reflects the kind of integrated approaches that will be required to deliver on the promise of eradication.

Through this new strategy, we believe the GPEI has re-envisioned its relationship with governments, deepened its commitment to polio-affected communities, made changes to empower and safeguard the frontline workforce, and expanded its partnerships to achieve broader impact in polio-priority geographies, alongside key innovations that will improve detection and response. The strategy also sets clear goals for strengthening the programme's gender-responsiveness, in recognition that the more women's meaningful participation and empowerment becomes a cornerstone of GPEI efforts, as outlined in its **Gender Equality Strategy**, the more progress towards eradication will be made. In further alignment with the Immunization Agenda 2030 (IA2030) and Gavi, the Vaccine Alliance's strategic plan (Gavi 5.0), the new strategy offers a more holistic approach to immunization and shares with IA2030 its principles of being people-centred, country-owned, partnership-based and data-guided.

With an updated strategy and a defined path to eradication, we must accelerate progress as we enter the 2022–2026 period. Stakeholders articulated the challenge well during the consultation process when they said, "Now is the time to do not just the good things or the hard things, but the very hard things."

As members of the Polio Oversight Board (POB), we join with the broader partnership in expressing our commitment to greater accountability on the path to eradication. In our meetings, POB members will routinely review the strategy's new monitoring and evaluation and risk management framework. We stand with you all, rededicated to polio eradication.

Working together and in close partnership with impacted countries, we can make up lost ground against polio during the COVID-19 pandemic, while continuing to leverage the programme's infrastructure to support fragile health systems. Even as COVID-19 continues to pose challenges to health programmes around the world, we recognize an opportunity to come back stronger in our effort to create a healthier and more equitable world, which includes eradicating one of the cruellest infectious diseases and thereby ensuring polio is no longer a threat to children and families anywhere in the world.

The GPEI Polio Oversight Board



Chris Elias

*President, Global Development Division,
Bill & Melinda Gates Foundation
2021 Chair of the Polio Oversight Board*



Mike McGovern

*Chair, International PolioPlus Committee,
Rotary International*



Seth Berkley

*Chief Executive Officer, Gavi, the Vaccine
Alliance*



Tedros Adhanom Ghebreyesus

WHO Director-General



Henrietta Fore

*Executive Director, United Nations Children's
Fund (UNICEF)*



Rochelle Walensky


*Director, US Centers for Disease Control and
Prevention (CDC)*

ACKNOWLEDGEMENTS

The GPEI engaged a broad set of stakeholders throughout the development of *Polio Eradication Strategy 2022–2026: Delivering on a promise*. The engagement process benefited from the generous inputs of country teams, national governments, donors and over 40 external and internal expert groups, many that encouraged the partnership to embrace a more holistic approach to polio eradication (see **Annex A**).

The contributions of all participants resulted in a strategy that seeks to overcome the remaining challenges through a recognition that polio eradication depends upon a spectrum of partners and a diversity of actors.

For their invaluable contributions to world health by vaccinating children and delivering other health services to their communities, the GPEI dedicates this strategy to frontline workers, and particularly those workers who have lost their lives. The strategy is also dedicated to children, adolescents and adults affected by polio and to the polio-affected advocates who have used their voice and experience to play a key role in the eradication effort.



预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23830

